title: Comparison of high titer Edmonston-Zagreb, Biken-CAM and Schwarz measles vaccines in Peruvian infants.
abstract: In an effort to identify the optimal dose and strain of measles vaccination for early immunization, Peruvian infants were randomly assigned to receive one of three measles vaccines in varying doses at 5 to 6 or 8 to 9 months of age. Edmonston-Zagreb vaccines were significantly (P < 0.001) more immunogenic than equivalent or higher titers of Schwarz or Biken-CAM vaccines as determined by neutralization antibody response 3 months after vaccination. Eighty-two percent of infants who received high titer Edmonston-Zagreb vaccine at 5 to 6 months of age developed protective concentrations of measles antibody, a response rate similar to that observed after standard titer Schwarz (81%) or high titer Biken-CAM vaccine (81%) at 8 to 9 months of age. No significant differences in the rates of fever, rash or other adverse events were noted by vaccine group 10 to 14 days after vaccination. Although the high titer vaccines are more immunogenic in young infants than standard vaccines, long term safety must be assured before these vaccines can be put into widespread use.
authors.affiliation: Department of International Health, Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD 21205.
authors.forename: S
authors.initials: S
authors.lastname: Berry
authors.forename: H
authors.initials: H
authors.lastname: Hernandez
authors.forename: R
authors.initials: R
authors.lastname: Kanashiro
authors.forename: M
authors.initials: M
authors.lastname: Campos
authors.forename: V
authors.initials: V
authors.lastname: Azabache
authors.forename: G
authors.initials: G
authors.lastname: Gomez
authors.forename: M
authors.initials: M
authors.lastname: Gutierrez
authors.forename: B
authors.initials: B
authors.lastname: Weirs
authors.forename: C
authors.initials: C
authors.lastname: De Quadros
authors.forename: N
authors.initials: N
authors.lastname: Halsey
mesh_terms: D000914:Antibodies, Viral / Q000096:biosynthesis*; D006801:Humans; D007223:Infant; D008458:Measles Vaccine / Q000009:adverse effects / Q000276:immunology*; D010568:Peru; D013045:Species Specificity; D014611:Vaccination
chemical_list: D000914:Antibodies, Viral; D008458:Measles Vaccine